Online inquiry

IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11392MR)

This product GTTS-WQ11392MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRA gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001347829.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5156
UniProt ID P16234
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11392MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ771MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ1878MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ9749MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ978MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-368
GTTS-WQ1858MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ8229MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ3532MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ1577MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-083
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW